Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

FKBP5 mRNA Expression Is a Biomarker for GR Antagonism.

Bali U, Phillips T, Hunt H, Unitt J.

J Clin Endocrinol Metab. 2016 Nov;101(11):4305-4312.

PMID:
27459525
2.

New selective glucocorticoid receptor modulators reverse amyloid-β peptide-induced hippocampus toxicity.

Pineau F, Canet G, Desrumaux C, Hunt H, Chevallier N, Ollivier M, Belanoff JK, Givalois L.

Neurobiol Aging. 2016 Sep;45:109-22. doi: 10.1016/j.neurobiolaging.2016.05.018.

PMID:
27459932
3.

Glucocorticoid antagonism limits adiposity rebound and glucose intolerance in young male rats following the cessation of daily exercise and caloric restriction.

Teich T, Dunford EC, Porras DP, Pivovarov JA, Beaudry JL, Hunt H, Belanoff JK, Riddell MC.

Am J Physiol Endocrinol Metab. 2016 Jul 1;311(1):E56-68. doi: 10.1152/ajpendo.00490.2015.

PMID:
27143556
4.

Identification of a selective glucocorticoid receptor modulator that prevents both diet-induced obesity and inflammation.

van den Heuvel JK, Boon MR, van Hengel I, Peschier-van der Put E, van Beek L, van Harmelen V, van Dijk KW, Pereira AM, Hunt H, Belanoff JK, Rensen PC, Meijer OC.

Br J Pharmacol. 2016 Jun;173(11):1793-804. doi: 10.1111/bph.13477.

PMID:
26990179
5.

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.

Moraitis AG, Auchus RJ.

Case Rep Endocrinol. 2016;2016:8453801. doi: 10.1155/2016/8453801.

6.

A novel combined glucocorticoid-mineralocorticoid receptor selective modulator markedly prevents weight gain and fat mass expansion in mice fed a high-fat diet.

Mammi C, Marzolla V, Armani A, Feraco A, Antelmi A, Maslak E, Chlopicki S, Cinti F, Hunt H, Fabbri A, Caprio M.

Int J Obes (Lond). 2016 Jun;40(6):964-72. doi: 10.1038/ijo.2016.13.

PMID:
26830012
7.

Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer.

Baker GM, Murphy T, Block T, Nguyen D, Lynch FJ.

Cancer Manag Res. 2015 Dec 4;7:361-8. doi: 10.2147/CMAR.S91546.

8.

Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.

Fein HG, Vaughan TB 3rd, Kushner H, Cram D, Nguyen D.

BMC Endocr Disord. 2015 Oct 27;15:63. doi: 10.1186/s12902-015-0059-5.

9.

Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.

Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C.

J Clin Endocrinol Metab. 2014 Oct;99(10):3718-27. doi: 10.1210/jc.2014-1843.

10.

Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats.

Beaudry JL, Dunford EC, Teich T, Zaharieva D, Hunt H, Belanoff JK, Riddell MC.

PLoS One. 2014 Mar 18;9(3):e91248. doi: 10.1371/journal.pone.0091248.

11.

Efficacy and safety of mifepristone for the treatment of psychotic depression.

Blasey CM, Block TS, Belanoff JK, Roe RL.

J Clin Psychopharmacol. 2011 Aug;31(4):436-40. doi: 10.1097/JCP.0b013e3182239191.

PMID:
21694614
12.

Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.

Gross C, Blasey CM, Roe RL, Belanoff JK.

Obesity (Silver Spring). 2010 Dec;18(12):2295-300. doi: 10.1038/oby.2010.51.

13.

Mifepristone treatment of olanzapine-induced weight gain in healthy men.

Gross C, Blasey CM, Roe RL, Allen K, Block TS, Belanoff JK.

Adv Ther. 2009 Oct;26(10):959-69. doi: 10.1007/s12325-009-0070-1.

PMID:
19888560
14.

A multisite trial of mifepristone for the treatment of psychotic depression: a site-by-treatment interaction.

Blasey CM, Debattista C, Roe R, Block T, Belanoff JK.

Contemp Clin Trials. 2009 Jul;30(4):284-8. doi: 10.1016/j.cct.2009.03.001. Erratum in: Contemp Clin Trials. 2010 Jan;31(1):134. Contemp Clin Trials. 2009 Sep;30(5):497.

PMID:
19318138
15.

Glucocorticoid receptor antagonists.

Clark RD.

Curr Top Med Chem. 2008;8(9):813-38. Review.

PMID:
18537690
16.

1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists with high functional activity.

Clark RD, Ray NC, Williams K, Blaney P, Ward S, Crackett PH, Hurley C, Dyke HJ, Clark DE, Lockey P, Devos R, Wong M, Porres SS, Bright CP, Jenkins RE, Belanoff J.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1312-7. doi: 10.1016/j.bmcl.2008.01.027.

PMID:
18226897
17.

Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression.

Nihalani ND, Schwartz TL.

Curr Opin Investig Drugs. 2007 Jul;8(7):563-9. Review.

PMID:
17659476
18.

Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.

DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G.

Biol Psychiatry. 2006 Dec 15;60(12):1343-9.

PMID:
16889757
19.

The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.

Beebe KL, Block T, Debattista C, Blasey C, Belanoff JK.

Behav Brain Res. 2006 Aug 10;171(2):225-9.

PMID:
16782211
20.

C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.

DeBattista C, Belanoff J.

Curr Alzheimer Res. 2005 Apr;2(2):125-9. Review.

PMID:
15974908
Items per page

Supplemental Content

Loading ...
Support Center